Astellas' ASP0113 Trial Failure Gives Merck's Prevymis Further CMV Boost
Merck's Prevymis should benefit from the failure of ASP0113 in a late-stage trial treating cytomegalovirus in certain kidney transplant patients.
Merck's Prevymis should benefit from the failure of ASP0113 in a late-stage trial treating cytomegalovirus in certain kidney transplant patients.